HK1223508A1 - 用於調節 甲基化的組合物和方法用於調節 甲基化的組合物和方法 - Google Patents

用於調節 甲基化的組合物和方法用於調節 甲基化的組合物和方法

Info

Publication number
HK1223508A1
HK1223508A1 HK16111814.3A HK16111814A HK1223508A1 HK 1223508 A1 HK1223508 A1 HK 1223508A1 HK 16111814 A HK16111814 A HK 16111814A HK 1223508 A1 HK1223508 A1 HK 1223508A1
Authority
HK
Hong Kong
Prior art keywords
dna
compositions
methods
modulating
methylation
Prior art date
Application number
HK16111814.3A
Other languages
English (en)
Inventor
Timothy Darren Eubank
Clay Braden Marsh
Duaa Dakhlallah
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of HK1223508A1 publication Critical patent/HK1223508A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16111814.3A 2013-08-16 2016-10-13 用於調節 甲基化的組合物和方法用於調節 甲基化的組合物和方法 HK1223508A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361867000P 2013-08-16 2013-08-16
PCT/US2014/051317 WO2015023967A2 (en) 2013-08-16 2014-08-15 Compositions and methods for modulating dna methylation

Publications (1)

Publication Number Publication Date
HK1223508A1 true HK1223508A1 (zh) 2017-08-04

Family

ID=52468818

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111814.3A HK1223508A1 (zh) 2013-08-16 2016-10-13 用於調節 甲基化的組合物和方法用於調節 甲基化的組合物和方法

Country Status (12)

Country Link
US (1) US20160199434A1 (zh)
EP (1) EP3032953A4 (zh)
JP (1) JP2016529257A (zh)
KR (1) KR20160046832A (zh)
CN (1) CN105979779A (zh)
AU (1) AU2014306496A1 (zh)
CA (1) CA2921005A1 (zh)
HK (1) HK1223508A1 (zh)
IL (1) IL244082A0 (zh)
MX (1) MX2016002014A (zh)
RU (1) RU2016109125A (zh)
WO (1) WO2015023967A2 (zh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2686520T3 (zh) 2011-06-06 2018-03-17
DK3007695T3 (da) 2013-06-13 2024-03-18 Akebia Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af anæmi
BR112017015852A2 (pt) 2015-01-23 2018-03-27 Akebia Therapeutics Inc forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1
EP3265582B1 (en) * 2015-03-06 2021-07-28 Vib Vzw Markers for determining tumor hypoxia
HRP20211862T1 (hr) 2015-04-01 2022-03-04 Akebia Therapeutics, Inc. Pripravci za i postupci liječenja anemije
CN108048529B (zh) * 2017-12-28 2021-01-19 广州市金圻睿生物科技有限责任公司 一种可稳定保存的肺癌甲基化基因检测试剂盒的质控品及应用
JPWO2019182037A1 (ja) * 2018-03-20 2021-03-11 国立大学法人東京工業大学 毒性が低減されたアンチセンスオリゴヌクレオチド
CN108441561A (zh) * 2018-04-19 2018-08-24 安徽达健医学科技有限公司 一种双重甲基化荧光定量pcr法用于膀胱癌早期筛查检测的试剂盒
AR114886A1 (es) 2018-05-09 2020-10-28 Akebia Therapeutics Inc Proceso para preparar ácido 2-[[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino]acético
CN116113421A (zh) * 2020-05-14 2023-05-12 阿莱兹精准医疗公司 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗
CN117965739A (zh) * 2024-02-21 2024-05-03 中山大学附属第一医院 用于宫颈癌相关基因甲基化检测的标志物、引物组合及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3026044T3 (pl) * 2006-06-26 2019-04-30 Akebia Therapeutics Inc Inhibitory prolilo-hydroksylazy i sposoby ich użycia
JP2014522410A (ja) * 2011-06-06 2014-09-04 アケビア セラピューティクス インコーポレイテッド がん治療のための方法として低酸素誘導因子−２αを安定化するための、化合物および組成物
JP6050337B2 (ja) * 2011-06-06 2016-12-21 ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド プロテオミクスに基づく、慢性副鼻腔炎の診断用検出方法
US20130022974A1 (en) * 2011-06-17 2013-01-24 The Regents Of The University Of Michigan Dna methylation profiles in cancer

Also Published As

Publication number Publication date
IL244082A0 (en) 2016-04-21
US20160199434A1 (en) 2016-07-14
CA2921005A1 (en) 2015-02-19
MX2016002014A (es) 2016-07-21
JP2016529257A (ja) 2016-09-23
RU2016109125A3 (zh) 2018-07-30
WO2015023967A2 (en) 2015-02-19
WO2015023967A3 (en) 2015-04-09
AU2014306496A1 (en) 2016-03-03
RU2016109125A (ru) 2017-09-22
KR20160046832A (ko) 2016-04-29
CN105979779A (zh) 2016-09-28
EP3032953A2 (en) 2016-06-22
EP3032953A4 (en) 2017-02-08

Similar Documents

Publication Publication Date Title
IL277196B (en) Methods and preparations for genome engineering
IL273205A (en) Preparations and methods
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
IL244081A0 (en) Preparations and methods for modulating RNA
HK1217608A1 (zh) 用於消耗品的方法及複合物
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
HK1217214A1 (zh) 用於增强核酸酶介導的基因破壞的方法和組合物
GB2527241B (en) Compositions and methods
EP3008181A4 (en) METHOD AND COMPOSITIONS FOR TARGETED DNA MODIFICATION
HK1223508A1 (zh) 用於調節 甲基化的組合物和方法用於調節 甲基化的組合物和方法
GB201308072D0 (en) Compositions and methods
GB201305813D0 (en) Compositions and methods
HK1217432A1 (zh) 多核苷酸轉染組合物和方法
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods